96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00048295 (ClinicalTrials.gov)	May 2002	29/10/2002	Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease	ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn’s Disease	Crohn's Disease	Drug: Alicaforsen	Isis Pharmaceuticals	NULL	Active, not recruiting	12 Years	N/A	Both	150	Phase 3	Belgium;Czech Republic;Germany;Italy;Poland;Spain
2	NCT00048113 (ClinicalTrials.gov)	September 2001	24/10/2002	Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease	ISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease	Crohn's Disease	Drug: Alicaforsen	Isis Pharmaceuticals	NULL	Completed	12 Years	N/A	Both	150	Phase 3	United States;Canada